Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
Arthritis & Rheumatology · 2026-10 · 78 (10) · 2089-2101
DOI: 10.1002/art.70134 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Arthritis & Rheumatology, online erschienen am 28.03.2026. Verfasst von Joseph F Merola und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center and O'Donnell School …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Psoriatic, Obesity. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Methods
TOGETHER‐PsA ( ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52‐week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center and O'Donnell School of Public Health, Dallas.
- Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle.
- Altoona Center for Clinical Research, Duncansville, Pennsylvania.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
- Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Philip Mease, Laura C Coates
Förderung
- Eli Lilly and Company
Zitieren
APA
Merola, J. F., Mease, P., Kivitz, A., Sattar, N., Coates, L. C., Aletaha, D., Kartman, C. E., Fischer, P., Sun, L., Martínez-Osuna, P., Kronbergs, A., Prajapati, P., Cardoso, A., Genovese, M. C., & Ogdie, A. (2026). Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis & Rheumatology, 78(10), 2089-2101. https://doi.org/10.1002/art.70134
Vancouver
Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis & Rheumatology. 2026;78(10):2089-2101. doi:10.1002/art.70134
BibTeX
@article{Merola2026,
author = {Merola, Joseph F and Mease, Philip and Kivitz, Alan and Sattar, Naveed and Coates, Laura C and Aletaha, Daniel and Kartman, Cynthia E and Fischer, Peter and Sun, Luna and Martínez-Osuna, Píndaro and Kronbergs, Andris and Prajapati, Purvi and Cardoso, Anabela and Genovese, Mark C and Ogdie, Alexis},
title = {Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {10},
pages = {2089--2101},
doi = {10.1002/art.70134}
}
EUVIMED